ASND logo

ASND

Ascendis Pharma A/S

$230.83
-$0.32(-0.14%)
59
Overall
20
Value
90
Tech
68
Quality
How is this score calculated?
Market Cap
$14.33B
Volume
908.47K
52W Range
$160.86 - $250.74
Target Price
$291.88
Order:

Income Statement

MetricTrendChart
2017
Dec
2018
Dec
2019
Dec
2020
Dec
2021
Dec
2022
Dec
2023
Dec
2024
Dec
REVENUE
Total Revenue
$1.5M$10.6M$13.3M$7.0M$7.8M$51.2M$266.7M$363.6M
Total Revenue
$1.5M$10.6M$13.3M$7.0M$7.8M$51.2M$266.7M$363.6M
COST OF GOODS SOLD
Cost of Revenue
------$80.8M$3.5M$12.1M$44.4M$44.3M
GROSS PROFIT
Gross Profit
$1.5M$10.6M$13.3M$7.0M$4.3M$39.0M$222.3M$319.4M
OPERATING EXPENSES
Operating Expenses
$113.1M$165.3M$240.1M$418.4M$456.0M$600.9M$677.9M$598.1M
Research & Development
$99.6M$140.3M$191.6M$260.9M$295.9M$379.6M$413.5M$307.0M
Research Expense
$99.6M$140.3M$191.6M$260.9M$295.9M$379.6M$413.5M$307.0M
Selling, General & Administrative
$13.5M$25.1M$48.5M$76.7M$160.2M$221.2M$264.4M$291.1M
Selling & Marketing Expenses
$13.5M$25.1M$48.5M$76.7M$160.2M$221.2M$264.4M$291.1M
General & Administrative Expenses
$-1.6M$-2.7M------------
Salaries & Wages
$-31.1M$-51.3M$-90.9M$-136.8M$-178.4M$-214.7M----
Depreciation & Amortization
$-734.0K$-880.0K$-6.7M$-9.4M$-11.0M$-11.7M----
Depreciation & Amortization
$-734.0K$127.0K$-6.7M$80.8M$-11.0M$-11.7M----
OPERATING INCOME
Operating income
$-111.5M$-154.8M$-226.8M$-411.5M$-451.8M$-561.8M$-455.5M$-278.8M
EBITDA
$-123.7M$-129.7M$-212.8M$-411.7M$-368.6M$-590.5M$-423.5M$-282.6M
NON-OPERATING ITEMS
Interest Expense (Non-Operating)
$-97.0K$-127.0K$-1.2M$-1.9M$-3.9M$-30.7M$44.1M$72.9M
Interest Income Operating
$65.0K--------------
Intinc
$923.0K$24.7M$17.8M$1.8M$59.7M$52.2M$31.5M$25.6M
Net Non-Operating Interest Income/Expense
$923.0K$24.7M$17.8M$1.8M$59.7M$52.2M$-12.6M$-74.4M
Other Income/Expense
$13.8M$321.0K$8.1M$9.5M$-15.9M$68.2M$18.4M$20.1M
Other Special Charges
$477.0K$394.0K$234.0K$219.0K$3.9M$-5.4M----
SPECIAL ITEMS
Special Income Charges
--$-127.0K$-1.2M--$-3.9M------
Impairment of Capital Assets
--------$3.9M------
PRE-TAX INCOME
EBIT
$-124.5M$-130.6M$-219.5M$-421.1M$-384.0M$-608.5M$-442.4M$-300.4M
Pre-Tax Income
$-124.4M$-130.5M$-218.3M$-419.2M$-380.1M$-577.8M$-486.5M$-373.2M
INCOME TAX
Tax Provision
$-477.0K$-394.0K$-234.0K$-219.0K$-367.0K$5.4M$7.3M$4.8M
NET INCOME
Net Income
$-123.8M$-130.1M$-218.1M$-419.0M$-379.7M$-583.2M$-493.8M$-378.1M
Net Income (Continuing Operations)
$-123.8M$-130.1M$-218.1M$-419.0M$-379.7M$-583.2M$-493.8M$-378.1M
Net Income (Discontinued Operations)
$-123.8M$-130.1M$-218.1M$-419.0M$-379.7M$-583.2M$-493.8M$-378.1M
Net Income (Common Stockholders)
$-123.8M$-130.1M$-218.1M$-419.0M$-379.7M$-583.2M$-493.8M$-378.1M
Normalized Income
------------$-357.6M$-369.5M
TOTALS
Total Expenses
$113.1M$165.3M$240.1M$418.4M$459.6M$613.0M$722.3M$642.4M
SHARE & EPS DATA
Average Shares Outstanding
$33.6M$41.1M$46.5M$50.6M$54.8M$56.1M$56.3M$57.9M
Average Shares Outstanding (Diluted)
$33.6M$41.0M$46.5M$50.6M$54.8M$56.1M$56.3M$57.9M
Shares Outstanding
$37.0M$42.1M$48.0M$53.8M$56.9M$57.2M$62.0M$62.0M
Basic EPS
$-3.68$-3.17$-4.69$-8.28----$-8.55$-6.53
Basic EPS (Continuing Operations)
----$-4.69$-8.28----$-8.55$-6.53
Diluted EPS
$-3.68--$-4.69$-8.28----$-8.55$-6.53
Diluted EPS (Continuing Operations)
------------$-8.55$-6.53
OTHER METRICS
Acquired In Process Rn D Income
$65.0K--------------
Acquisition Expense
----------$50.5M----
Depletion
--$127.0K--$80.8M--------
Earnings from equity interest
--$-321.0K$-8.1M$-9.5M$12.0M$-17.7M$-18.4M$-20.1M
Earnings From Equity Interest Net Of Tax
--$-321.0K$-8.1M$-9.5M$12.0M$-17.7M$-18.4M$-20.1M
Fees
--$9.4M$2.7M$2.6M$2.4M$2.5M----
Interest Expense Operating
$13.8M----------$44.1M--
Loss And Loss Adjustment Expected Incurred
----$1.2M----------
Marketing Expense
--------$3.9M------
Non Recurring Operation Expense
----$1.2M----------
Other Costof Revenue
------------$44.4M$44.3M
Other Gand A
$-1.6M$-2.7M------------
Other Impairment Of Capital Assets
$13.8M--------------
Other Write Down
----$1.2M----------
Other Write Off
----------$50.5M----
Realized Capital Gain
--$17.0K----$3.9M------
Rent And Landing Fees
$-1.6M$-2.7M------------
Selling Expense
$13.5M$25.1M$48.5M$76.7M$160.2M$221.2M----
Write Down
--$127.0K----$3.9M------

Financial data is updated quarterly and may not reflect the most recent earnings.

ABCD
1SymbolPriceChangeVol
2ASND$230.83-0.1%908.47K
3
4
5
6

Get Ascendis Pharma A/S Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.